AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca PLC (AZN) Q3 2026 Earnings Call October 30, 2026 10:30 AM EDT
Company Participants
Joris Silon – Head of Investor Relations
Pascal Soriot – CEO & Executive Director
Aradhana Sarin – CFO & Executive Director
David Fredrickson – Executive Vice-President of Oncology Haematology Business Unit
Susan Galbraith – Executive Vice President of Oncology R&D
Ruud Dobber – Executive Vice-President of BioPharmaceuticals Business Unit
Sharon Barr – Executive Vice-President of BioPharmaceuticals R&D
Marc Dunoyer – CEO of Alexion & Chief Strategy Officer
Iskra Reic – Executive Vice President of International
Conference Call Participants
Mattias Häggblom – Nordea Markets, Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
Sachin Jain – BofA Securities, Research Division
Steve Scala – TD Cowen, Research Division
Richard Vosser – JPMorgan Chase & Co, Research Division
Graham Glyn Parry – Citigroup Inc., Research Division
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Thibault Boutherin – Morgan Stanley, Research Division
Trung Huynh – RBC Capital Markets, Research Division
James Gordon – Barclays Bank PLC, Research Division
Peter Verdult – BNP Paribas, Research Division
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Michael Leuchten – Jefferies LLC, Research Division
Presentation
Operator
Welcome to AstraZeneca’s 9 Months and Q3 2026 Webinar for Investors and Analysts. Before handing over to AstraZeneca, I’d like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements regarding AstraZeneca’s operations and financial performance.
Although we believe our expectations are based on reasonable assumptions, forward-looking statements, by their nature, involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these statements. Any forward-looking statements made during this call reflect the knowledge and information available at the time of the call. The company undertakes no obligation to update
